Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage III non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2143-2150

  Kostakoglu, Lale ^a   Schöder, Heiko ^b   Johnson, Jeffrey L ^c   Hall, Nathan C ^d   Schwartz, Lawrence H ^e   Straus, David J ^b   Lacasce, Ann S ^f   Jung, Sin Ho ^c   Bartlett, Nancy L ^g   Canellos, George P ^f   Cheson, Bruce D ^h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

interim PET CT; Lymphoma and Hodgkin disease; therapy response

Indexed keywords

DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; VINBLASTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ADULT; AGED; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 84867186026     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.676173     Document Type: Article

References (41)

1. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. J Clin Oncol 1986;4:160-164. (Pubitemid 16161030)
2. Haw R, Sawka CA, Franssen E, et al. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol 1994;12:1074-1084. (Pubitemid 24145339)
3. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642. (Pubitemid 46237440)
4. Radford JA, Cowan RA, Flanagan M, et al. The signif cance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988;6:940-946.
5. Lewis E, Bernardino ME, Salvador PG, et al. Post-therapy CT detected mass in lymphoma patients: is it viable tissue? J Comput Assist Tomogr 1982;6:792-795. (Pubitemid 12097825)
6. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168. (Pubitemid 41418320)
7. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-59. (Pubitemid 43053523)
8. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006;91:475-481.
9. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006;107:2678-2687. (Pubitemid 44845624)
10. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296-1300. (Pubitemid 44288221)
11. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]f uoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
12. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-f uorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906-1914.
13. Cheson BD, Pf stner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. (Pubitemid 350002966)
14. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET Scan in Lymphoma. Leuk Lymphoma 2009;50:1257-1260.
15. Barrington SF, Qian W, Somer E, et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824-1833.
16. Straus DJ, Johnson JL, Lacasce AS, et al. Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood 2011;117:5314-5320.
17. Cheson BD, Horning SJ, Coifier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
18. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by Integrated International Workshop Criteria and f uorine-18-f uorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652-4661. (Pubitemid 46224067)
19. Kaplan DL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Peto R, Peto J. Asymptotically ef cient rank invariant test procedures. J R Stat Soc A 1972;135:185-207.
21. McNemar Q. Note on the sampling error of the dif erence between correlated proportions or percentages. Psychometrika 1947;12:153-157.
22. Barnes JA, Lacasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol 2011;22:910-915.
23. Canellos GP, Abramson JS, Fisher DC, et al. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010;28:1611-1615.
24. Eich HT, Diehl V, Gorgen H, et al. Intensif ed chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. J Clin Oncol 2010;28:4199-4206.
25. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
26. Zinzani PL, Rigacci L, Stefoni V, et al. Early interim (18)F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 2012;39:4-12.
27. Marc APE, Reman O, Federico M, et al. First report on the H10 EORTC/GELA/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II Hodgkin's lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Blood 2009;114(Suppl. 1): Abstract 97.
28. Fitoussi O, Brice P, Hirt S, et al. Early interim FDG-PET scan in localised Hodgkin lymphoma: evaluation of practice in 5 French centers. Blood 2008;112(Suppl. 1): Abstract 4935.
29. Stefoni V, Broccoli A, Alinari L, et al. Predictive role of early interim FDG-PET in Hodgkin lymphoma. Blood 2009;114(Suppl. 1): Abstract 1659.
30. Radford J, O'Doherty M, Barrington S, et al. Results of the 2nd planned interim analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and negative FDG-PET scan after 3 cycles ABVD. Blood 2008;112(Suppl. 1): Abstract 369.
31. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483-3489. (Pubitemid 39564416)
32. Zijlstra JM, Comans E F, van Lingen A, et al. FDG PET in lymphoma : the need for standardization of interpretation. An observer variation study. Nucl Med Commun 2007;28:798-803. (Pubitemid 47345712)
33. Andre M, Vander Borght T, Bosly A. Interim FDG-PET scan in Hodgkin's lymphoma: hopes and caveats. Adv Hematol 2011;2011:430679.
34. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50:21S-30S.
35. Sher DJ, Mauch PM, Van Den Abbeele A, et al. Prognostic signif cance of mid-and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848-1853.
36. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688. (Pubitemid 36612950)
37. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
38. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011;38:1064-1071.
39. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-7071. (Pubitemid 19013983)
40. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163-169. (Pubitemid 16140378)
41. Baish JW, Jain R. Fractals and cancer. Cancer Res 2000;60:3683-3688. (Pubitemid 32204551)